Augmenting Anti-Cancer Natural Products with a Small Molecule Adjuvant
Aquatic microbes produce diverse secondary metabolites with interesting biological activities. Cytotoxic metabolites have the potential to become lead compounds or drugs for cancer treatment. Many cytotoxic compounds, however, show undesirable toxicity at higher concentrations. Such undesirable acti...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2014-12-01
|
| Series: | Marine Drugs |
| Subjects: | |
| Online Access: | http://www.mdpi.com/1660-3397/13/1/65 |
| _version_ | 1811301132214992896 |
|---|---|
| author | Paul G. Wahome Kevin R. Beauchesne Anna C. Pedone John Cavanagh Christian Melander Paul Zimba Peter D. R. Moeller |
| author_facet | Paul G. Wahome Kevin R. Beauchesne Anna C. Pedone John Cavanagh Christian Melander Paul Zimba Peter D. R. Moeller |
| author_sort | Paul G. Wahome |
| collection | DOAJ |
| description | Aquatic microbes produce diverse secondary metabolites with interesting biological activities. Cytotoxic metabolites have the potential to become lead compounds or drugs for cancer treatment. Many cytotoxic compounds, however, show undesirable toxicity at higher concentrations. Such undesirable activity may be reduced or eliminated by using lower doses of the cytotoxic compound in combination with another compound that modulates its activity. Here, we have examined the cytotoxicity of four microbial metabolites [ethyl N-(2-phenethyl) carbamate (NP-1), Euglenophycin, Anabaenopeptin, and Glycolipid 652] using three in vitro cell lines [human breast cancer cells (MCF-7), mouse neuroblastoma cells (N2a), and rat pituitary epithelial cells (GH4C1)]. The compounds showed variable cytotoxicity, with Euglenophycin displaying specificity for N2a cells. We have also examined the modulatory power of NP-1 on the cytotoxicity of the other three compounds and found that at a permissible concentration (125 µg/mL), NP-1 sensitized N2a and MCF-7 cells to Euglenophycin and Glycolipid 652 induced cytotoxicity. |
| first_indexed | 2024-04-13T07:03:27Z |
| format | Article |
| id | doaj.art-9530bf9c56b448d49544ab96070b5207 |
| institution | Directory Open Access Journal |
| issn | 1660-3397 |
| language | English |
| last_indexed | 2024-04-13T07:03:27Z |
| publishDate | 2014-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Marine Drugs |
| spelling | doaj.art-9530bf9c56b448d49544ab96070b52072022-12-22T02:57:03ZengMDPI AGMarine Drugs1660-33972014-12-01131657510.3390/md13010065md13010065Augmenting Anti-Cancer Natural Products with a Small Molecule AdjuvantPaul G. Wahome0Kevin R. Beauchesne1Anna C. Pedone2John Cavanagh3Christian Melander4Paul Zimba5Peter D. R. Moeller6Biosortia Pharmaceuticals, 565 Metro Place South, Suite 300, Dublin, OH 43017, USABiosortia Pharmaceuticals, 565 Metro Place South, Suite 300, Dublin, OH 43017, USABiosortia Pharmaceuticals, 565 Metro Place South, Suite 300, Dublin, OH 43017, USADepartment of Molecular & Structural Biochemistry, North Carolina State University, Campus Box 7622, 128 Polk Hall, Raleigh, NC 27695, USADepartment Chemistry, North Carolina State University, 2620 Yarbrough Drive, Box 8204, Raleigh, North Carolina 27695, USADepartment of Life Sciences, Texas A&M Corpus Christi, 6300 Ocean Drive, Corpus Christi, TX 78412, USAToxin/Natural Products Chemistry, National Ocean Service/NOAA, Hollings Marine Lab, 331 Fort Johnson Road, Charleston, SC 29412, USAAquatic microbes produce diverse secondary metabolites with interesting biological activities. Cytotoxic metabolites have the potential to become lead compounds or drugs for cancer treatment. Many cytotoxic compounds, however, show undesirable toxicity at higher concentrations. Such undesirable activity may be reduced or eliminated by using lower doses of the cytotoxic compound in combination with another compound that modulates its activity. Here, we have examined the cytotoxicity of four microbial metabolites [ethyl N-(2-phenethyl) carbamate (NP-1), Euglenophycin, Anabaenopeptin, and Glycolipid 652] using three in vitro cell lines [human breast cancer cells (MCF-7), mouse neuroblastoma cells (N2a), and rat pituitary epithelial cells (GH4C1)]. The compounds showed variable cytotoxicity, with Euglenophycin displaying specificity for N2a cells. We have also examined the modulatory power of NP-1 on the cytotoxicity of the other three compounds and found that at a permissible concentration (125 µg/mL), NP-1 sensitized N2a and MCF-7 cells to Euglenophycin and Glycolipid 652 induced cytotoxicity.http://www.mdpi.com/1660-3397/13/1/65anti-cancer agentscytotoxicitynatural productstoxinsadjuvantsmall molecule |
| spellingShingle | Paul G. Wahome Kevin R. Beauchesne Anna C. Pedone John Cavanagh Christian Melander Paul Zimba Peter D. R. Moeller Augmenting Anti-Cancer Natural Products with a Small Molecule Adjuvant Marine Drugs anti-cancer agents cytotoxicity natural products toxins adjuvant small molecule |
| title | Augmenting Anti-Cancer Natural Products with a Small Molecule Adjuvant |
| title_full | Augmenting Anti-Cancer Natural Products with a Small Molecule Adjuvant |
| title_fullStr | Augmenting Anti-Cancer Natural Products with a Small Molecule Adjuvant |
| title_full_unstemmed | Augmenting Anti-Cancer Natural Products with a Small Molecule Adjuvant |
| title_short | Augmenting Anti-Cancer Natural Products with a Small Molecule Adjuvant |
| title_sort | augmenting anti cancer natural products with a small molecule adjuvant |
| topic | anti-cancer agents cytotoxicity natural products toxins adjuvant small molecule |
| url | http://www.mdpi.com/1660-3397/13/1/65 |
| work_keys_str_mv | AT paulgwahome augmentinganticancernaturalproductswithasmallmoleculeadjuvant AT kevinrbeauchesne augmentinganticancernaturalproductswithasmallmoleculeadjuvant AT annacpedone augmentinganticancernaturalproductswithasmallmoleculeadjuvant AT johncavanagh augmentinganticancernaturalproductswithasmallmoleculeadjuvant AT christianmelander augmentinganticancernaturalproductswithasmallmoleculeadjuvant AT paulzimba augmentinganticancernaturalproductswithasmallmoleculeadjuvant AT peterdrmoeller augmentinganticancernaturalproductswithasmallmoleculeadjuvant |